What this pack is
Lovenox is the brand name in this record; enoxaparin is the generic name. Read both together with the dosage form (injectable product).
PACK CHECK · MARKET FIRST
LovenoxGeneric nameenoxaparin
How this medicine works
The current label describes enoxaparin as a low-molecular-weight heparin whose anticoagulant activity is linked to binding antithrombin III, with predominant anti-factor Xa and anti-factor IIa activity. This explains a label-described pathway, not whether anyone needs anticoagulation, their individual risk, injection amount, schedule, monitoring, co-use or switching.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Lovenox
- Generic name
- enoxaparin
- Dosage-form class
- Enoxaparin sodium injection: prefilled single-dose syringes and a multiple-dose vial (as listed in the current U.S. label)
- Route
- Subcutaneous / intravenous injection
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
A vial concentration, unit-per-mL value or device marking identifies the exact labelled product. It does not calculate an individual's amount, timing, administration, missed-use action, combination or switch.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Prescribing information revised May 2025; DailyMed SPL v33 published 29 May 2026
40 mg/0.4 mL; 100 mg/mL; 10 single-dose prefilled syringes
- Product code
- NDC 0075-0620-40
- Form and route
- enoxaparin sodium injection; single-dose prefilled syringe · subcutaneous or intravenous (label scope; this page does not determine an individual's route)
- Labelled concentration
- 100 mg/mL (labelled concentration; not an individual injection amount)Product identity, not an individual dose
- Container
- single-dose prefilled syringe with automatic safety device · 0.4 mL
- Delivery device
- automatic safety device
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-20; actual marketing, stock and availability are not established.
- enoxaparin sodium
- 100 mg/mLlabelled concentration; not an individual injection amount
- enoxaparin sodium
- 40 mglabelled amount in each single-dose prefilled syringe; not an individual administration instruction
- Package
- 10 × single-dose prefilled syringes per carton
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
LOVENOX label reading: mg, mL, concentration and syringe/vial must be checked together
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module only helps read brand, generic name, container, concentration, NDC and serious-risk warnings in the current U.S. label; it does not generate an individual's injection amount, frequency, duration, missed-use action, stopping, switching or combination plan.
- Check LOVENOX, enoxaparin sodium, the exact mg/mL, mg per syringe (or vial), container type, NDC, target market and label version together. Milligrams, millilitres and mg/mL on a package identify the product; they are not a web answer for an individual's injection amount.
- Single-dose prefilled syringes and a multiple-dose vial are different containers. Even with the same generic name, similar numbers or the same ‘enoxaparin’ wording, do not self-withdraw, transfer, divide, make up, share, adjust by markings or replace one container with another.
- Enoxaparin, unfractionated heparin, warfarin, apixaban, rivaroxaban, aspirin, clopidogrel, ibuprofen/naproxen and some supplements can make a complete medicine-list review important. Do not self-combine, alternate, pause or substitute merely because labels mention anticoagulation, clot prevention or pain relief.
- For planned spinal/epidural anaesthesia, lumbar puncture, surgery or dental procedures, or a fall, head injury, unusual or heavy bleeding, black stools, vomiting blood, marked dizziness/fainting or another acute concern, promptly contact the prescribing team or local urgent-care support; this page does not decide self-stopping or restarting.
- Neither the label's anticoagulant mechanism nor package strength can answer why a person needs anticoagulation, when or how much to inject, whether another anticoagulant can replace it, or what to do after a missed use. For those answers, take the actual package and complete medicine list to a pharmacist or clinician.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. LOVENOX enoxaparin sodium public label (Sanofi-Aventis U.S. LLC; SPL v33) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Lovenox (enoxaparin). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Lovenox is the brand in this record and enoxaparin is the active-ingredient name. Check both with the dosage form (Enoxaparin sodium injection: prefilled single-dose syringes and a multiple-dose vial (as listed in the current U.S. label)) and the market on the actual pack.
Read the labelled strength in context
mg/mL, mg per vial or a total volume describes the labelled concentration or pack identity of an injectable product. It is not an individual infusion amount, preparation instruction or schedule.
Check the exact injection presentation
For an injectable or infusion presentation, verify the route, concentration, container and device in the exact current label. Do not transfer, share, prepare or substitute it from this page.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a severe reaction, fainting, difficulty breathing or sudden worsening symptoms around an injection or infusion, use the local treatment team or emergency service now. Do not wait for a website reply or alter preparation, infusion or another medicine yourself.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How enoxaparin works: the label describes predominant anti-factor Xa and anti-factor IIa activity
- ‘Affects clotting factors’ does not let a webpage determine the cause of chest pain, leg swelling, breathing trouble, bruising, bleeding or a laboratory result, nor replace professional assessment of clotting, bleeding, kidney function, weight, age, pregnancy, procedure plans and the full medicine list.
- A shared anticoagulant class, clotting-pathway effect or unit/concentration wording on a package does not make enoxaparin self-equivalent, combinable, alternatable or convertible with unfractionated heparin, warfarin, direct oral anticoagulants, antiplatelet medicines or another enoxaparin package.
- A mechanism page cannot manage unusual bleeding, allergy, neurologic symptoms, suspected misuse, procedure/epidural concerns or another acute severe problem. With these concerns, prioritise local clinicians, pharmacists or urgent support rather than self-adjusting from mechanism text.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
SOURCE-TRACEABLE ARCHIVE
Lovenoxenoxaparin
This page includes an exact current U.S. public-label package panel for Lovenox, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the current label
The current U.S. LOVENOX label lists Initial U.S. Approval: 1993; that year does not establish approval or product status in another market.
DailyMed: current LOVENOX public label, SPL v33 ↗Current prescribing-information revision month
The current label text lists Revised: 5/2025; this remains separate from the DailyMed publication date.
DailyMed: current LOVENOX public label, SPL v33 ↗DailyMed SPL v33 published
DailyMed lists 29 May 2026 as the current SPL v33 Published Date; this date is not interpreted as a new individual-treatment recommendation.
DailyMed: current LOVENOX public label, SPL v33 ↗
MARKET SCOPE
Market-record boundary
United States
Current public label and one exact package panel linkedThe dossier image corresponds only to the 40 mg/0.4 mL, ten single-dose-syringe panel, NDC 0075-0620-40; it does not establish actual marketing, stock, availability or the status of another package.
Mainland China and other markets
Market record not establishedNo local trade name, approval, strength, package, supply, interchangeability or use plan is inferred from the U.S. label.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Does 40 mg/0.4 mL mean everyone should inject that whole syringe?
No. It identifies one U.S.-labelled package. This page provides no personal injection amount, frequency, duration or missed-use action; use the exact prescription, package in hand and pharmacist/clinician review.
Can LOVENOX self-replace another anticoagulant or antiplatelet medicine?
No. A shared ‘anticoagulation/clot prevention’ description does not establish interchangeability. A professional who knows the specific reason, procedure plan, kidney function, bleeding risk and complete medicine list must review it item by item.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.